Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis
- PMID: 20652159
- PMCID: PMC2918484
- DOI: 10.1155/2010/872570
Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis
Abstract
Background: Many previous studies have evaluated the histopathological features of tumours as risk factors for postoperative recurrence in hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). However, there have been few large studies investigating the relationship between cyclooxygenase-2 (COX-2) expression in noncancerous regions of the liver and postoperative recurrence in the remnant liver, especially in HBV-related HCC.
Objective: To evaluate the significance of COX-2 expression levels in noncancerous liver regions as a prognostic indicator of HCC in patients with HBV-related cirrhosis.
Methods: A total of 124 patients who underwent curative resection for HCC were reviewed retrospectively. Immunohistochemistry was used to evaluate the expression of COX-2 in noncancerous liver tissue. Clinicopathological variables were compared between patients with high COX-2 expression (n=58 [COX-2-positive group]) and patients with low COX-2 expression (n=66; [COX-2-negative group]). Univariate and multivariate analyses were performed to identify factors that affected disease recurrence.
Results: There was a significant correlation between COX-2 expression and alanine aminotransferase levels and vascular invasion. The recurrence-free survival rates in the COX-2-positive group were significantly lower than the rates in the COX-2-negative group. On multivariate analysis, the overexpression of COX-2 in noncancerous liver regions was found to be an unfavourable prognostic indicator for the recurrence of HCC.
Conclusions: The results of the current study suggest that overexpression of COX-2 in noncancerous liver regions is an independent and significant indicator predictive of early recurrence of HCC in patients with HBV-related cirrhosis.
CONTEXTE :: De nombreuses études ont évalué les caractéristiques cytopathologiques des tumeurs comme facteurs de risque de récurrence postopératoire du cancer hépatocellulaire (CHC) associé au virus de l’hépatite B (VHB). Toutefois, peu de grandes études ont porté sur le lien entre l’expression de la cyclooxygénase 2 (COX-2) dans les zones non cancéreuses du foie et la récurrence postopératoire dans les tissus hépatiques résiduels, surtout dans le CHC lié au VHB.
OBJECTIF :: Évaluer le rôle des taux d’expression de la COX-2 dans les zones hépatiques non cancéreuses comme indicateurs pronostiques du CHC chez des patients souffrant d’une cirrhose liée au VHB.
MÉTHODES :: En tout, 124 patients ayant subi une résection curative pour CHC ont été examinés de manière rétrospective. Les auteurs ont utilisé les tests immunohistochimiques pour évaluer l’expression de la COX-2 dans les tissus hépatiques non cancéreux. Ils ont comparé les variables clinicopathologiques des patients présentant une forte expression de la COX-2 (n = 58 [groupe COX-2-positif]) à celles des patients présentant une faible expression de la COX-2 (n = 66 [groupe COX-2-négatif]). Des analyses uni- et multivariées ont permis d’identifier les facteurs ayant influé sur la récurrence de la maladie.
RÉSULTATS :: On a noté une corrélation négative entre l’expression de la COX-2 et les taux d’alanine aminotransférase et l’envahissement vasculaire. Les taux de survie sans récurrence dans le groupe COX-2-positif ont été significativement plus bas que dans le groupe COX-2-négatif. À l’analyse multivariée, la surexpression de la COX-2 dans les zones hépatiques non cancéreuses s’est révélée être un indicateur pronostique défavorable à l’égard de la récurrence du CHC.
CONCLUSIONS :: Les résultats de la présente étude donnent à penser que la surexpression de la COX-2 dans les zones hépatiques non cancéreuses est un indicateur indépendant et significatif qui permet de prédire la récurrence précoce du CHC chez des patients souffrant d’une cirrhose liée au VHB.
Figures



Similar articles
-
Preoperative γ-glutamyl transpeptidase to platelet ratio (GPR) is an independent prognostic factor for HBV-related hepatocellular carcinoma after curative hepatic resection.Medicine (Baltimore). 2016 Jul;95(27):e4087. doi: 10.1097/MD.0000000000004087. Medicine (Baltimore). 2016. PMID: 27399101 Free PMC article.
-
Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.World J Gastroenterol. 2015 Apr 28;21(16):4933-45. doi: 10.3748/wjg.v21.i16.4933. World J Gastroenterol. 2015. PMID: 25945007 Free PMC article.
-
Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience.J Gastroenterol Hepatol. 2007 Nov;22(11):1936-41. doi: 10.1111/j.1440-1746.2006.04619.x. J Gastroenterol Hepatol. 2007. PMID: 17914973
-
Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma.J Gastroenterol Hepatol. 2007 Aug;22(8):1249-55. doi: 10.1111/j.1440-1746.2006.04367.x. J Gastroenterol Hepatol. 2007. PMID: 17688665
-
Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.World J Gastroenterol. 2015 Jul 21;21(27):8249-55. doi: 10.3748/wjg.v21.i27.8249. World J Gastroenterol. 2015. PMID: 26217076 Free PMC article. Review.
Cited by
-
Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2.Cancer Manag Res. 2019 Apr 9;11:2831-2848. doi: 10.2147/CMAR.S183376. eCollection 2019. Cancer Manag Res. 2019. PMID: 31114336 Free PMC article.
-
A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment.Hepatol Int. 2016 Sep;10(5):799-806. doi: 10.1007/s12072-016-9704-y. Epub 2016 Feb 4. Hepatol Int. 2016. PMID: 26846471 Free PMC article. Clinical Trial.
-
Cyclooxygenase-2 Inhibitor Reduces Hepatic Stiffness in Pediatric Chronic Liver Disease Patients Following Kasai Portoenterostomy.Yonsei Med J. 2016 Jul;57(4):893-9. doi: 10.3349/ymj.2016.57.4.893. Yonsei Med J. 2016. PMID: 27189282 Free PMC article. Clinical Trial.
-
Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.Gut. 2019 Feb;68(2):347-358. doi: 10.1136/gutjnl-2017-315348. Epub 2018 Feb 2. Gut. 2019. PMID: 29420225 Free PMC article.
-
Effect of Ginkgo biloba extract on the expressions of Cox-2 and GST-Pi in rats with hepatocellular carcinoma risk.Afr Health Sci. 2014 Mar;14(1):37-48. doi: 10.4314/ahs.v14i1.7. Afr Health Sci. 2014. PMID: 26060456 Free PMC article.
References
-
- El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–50. - PubMed
-
- Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90Yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583–92. - PubMed
-
- Akriviadis EA, Llovet JM, Efremidis SC, et al. Hepatocellular carcinoma. Br J Surg. 1998;85:1319–31. - PubMed
-
- Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908–16. - PubMed
-
- Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in noncancerous liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res. 1999;5:4005–12. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials